Compugen Showcases Innovative AI/ML Research at Global Conferences on Cancer Immunotherapy
Compugen Ltd., a renowned clinical-stage company specializing in cancer immunotherapy, has announced its participation in several prominent international scientific conferences, where it will present groundbreaking research driven by Artificial Intelligence (AI) and Machine Learning (ML). This research aims to deepen the understanding of complex cancer biology, particularly in terms of immune evasion and resistance to immunotherapy.
The first of these international events is the 2025 Annual Congress of the European Association for Cancer Research, scheduled to take place from June 16-19 in Lisbon, Portugal. Compugen will showcase a poster titled "Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes". This presentation will be led by Amir Toporik from the Computational Discovery team and is set for June 18, 2025. The study focuses on Triple-Negative Breast Cancer (TNBC), a subtype notoriously recognized for its aggressive nature and the challenges it poses in treatment, especially concerning immunotherapy effectiveness.
Following this, from July 20-24, 2025, in Liverpool, UK, Compugen will feature another pivotal research piece at the International Society for Computational Biology and European Conference on Computational Biology. The poster titled "Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms" is set to further explore the intricacies of immune response in TNBC, presented by Itamar Borukhov, Ph.D., also from Compugen's Computational Discovery unit.
Both research presentations aim to highlight Compugen’s robust capabilities in utilizing computational tools—specifically their proprietary predictive computational discovery platform known as Unigen™. This platform is instrumental in identifying new drug targets and biological pathways essential for developing effective cancer immunotherapies.
Beyond showcasing their research, Compugen has made it clear that details surrounding these presentations will be available on their official website, allowing wider access to their findings post-conferences. These events underscore the importance of computational biology in shaping the future landscape of cancer treatment and the vital role of AI and ML in enhancing research outcomes.
Compugen has a substantial pipeline of immunotherapy products in various development stages. Notably, the company possesses two proprietary drug candidates in Phase 1 development: COM701, an innovative anti-PVRIG antibody, and COM902, a potential best-in-class antibody targeting TIGIT. Additionally, they are collaborating with AstraZeneca for the development of a bispecific antibody, Rilvegostomig, which combines PD-1/TIGIT components derived from Compugen's own research.
Moreover, a promising candidate, GS-0321, which is a high-affinity anti-IL-18 binding protein antibody, is also in Phase 1 and is licensed to Gilead. Compugen's ongoing research programs in early-stage immuno-oncology are focused on discovering new mechanisms to enhance anti-cancer immunity.
Headquartered in Holon, Israel, Compugen operates with additional offices in San Francisco, California. Its shares are publicly traded on both the Nasdaq and the Tel Aviv Stock Exchange, representing a commitment to advancing cancer immunotherapy through innovation and scientific excellence.